Cytodyn Inc (CYDY)

[Saltz]

The next news will be:

August: Combo PE Data. Hopefully strong with many going on to extension that have completed the trial.

September: Face to face with FDA either granting or denying BTD. BLA pathway will also be defined.

Other positives to come from FDA face to face could be expanded label to increase patient population beyond Combo. This is enormous as it would increase immediate market value.

After face to face with FDA the pathway to approval and monetization will be defined. If everything goes right we could see an organic rise in SP to avoid a R/S.

Management believes after those events is the most opportune time to go for a major raise. The positive driving Pro-140 is the absence of ANY bad news. As long as the trials continue to reflect strong efficacy and a stellar safety record we will cross the goal line. The FDA will control the timeline with their decision regarding BTD which will impact the speed at which we proceed.

The next couple of months are going to tell the story.